Pharmacokinetics/pharmacodynamics of colistin and polymyxin B: are we there yet?

Nation, 2015, Framework for optimisation of the clinical use of colistin and polymyxin B: the Prato polymyxin consensus, Lancet Infect Dis, 15, 225, 10.1016/S1473-3099(14)70850-3 Li, 2006, Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections, Lancet Infect Dis, 6, 589, 10.1016/S1473-3099(06)70580-1 Koch-Weser, 1970, Adverse effects of sodium colistimethate. Manifestations and specific reaction rates during 317 courses of therapy, Ann Intern Med, 72, 857, 10.7326/0003-4819-72-6-857 US Centers for Disease Control and Prevention (CDC), 2013 Velkov, 2010, Structure–activity relationships of polymyxin antibiotics, J Med Chem, 53, 1898, 10.1021/jm900999h Baron, 2016, Molecular mechanisms of polymyxin resistance: knowns and unknowns, Int J Antimicrob Agents, 10.1016/j.ijantimicag.2016.06.023 Nation, 2014, Colistin and polymyxin B: peas in a pod, or chalk and cheese?, Clin Infect Dis, 59, 88, 10.1093/cid/ciu213 Gales, 2011, Contemporary activity of colistin and polymyxin B against a worldwide collection of Gram-negative pathogens: results from the SENTRY Antimicrobial Surveillance Program (2006–09), J Antimicrob Chemother, 66, 2070, 10.1093/jac/dkr239 Humphries, 2015, Susceptibility testing of the polymyxins: where are we now?, Pharmacotherapy, 35, 22, 10.1002/phar.1505 European Committee on Antimicrobial Susceptibility Testing Clinical and Laboratory Standards Institutes, 2014 European Committee on Antimicrobial Susceptibility Testing Trimble, 2016, Polymyxin: alternative mechanisms of action and resistance, Cold Spring Harb Perspect Med, 6, 10.1101/cshperspect.a025288 Olaitan, 2014, Mechanisms of polymyxin resistance: acquired and intrinsic resistance in bacteria, Front Microbiol, 5, 643, 10.3389/fmicb.2014.00643 Moffatt, 2010, Colistin resistance in Acinetobacter baumannii is mediated by complete loss of lipopolysaccharide production, Antimicrob Agents Chemother, 54, 4971, 10.1128/AAC.00834-10 Plachouras, 2009, Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by Gram-negative bacteria, Antimicrob Agents Chemother, 53, 3430, 10.1128/AAC.01361-08 Mohamed, 2012, Application of a loading dose of colistin methanesulfonate in critically ill patients: population pharmacokinetics, protein binding, and prediction of bacterial kill, Antimicrob Agents Chemother, 56, 4241, 10.1128/AAC.06426-11 Karaiskos, 2015, Colistin population pharmacokinetics after application of a loading dose of 9 MU colistin methanesulfonate in critically ill patients, Antimicrob Agents Chemother, 59, 7240, 10.1128/AAC.00554-15 Garonzik, 2011, Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients, Antimicrob Agents Chemother, 55, 3284, 10.1128/AAC.01733-10 Karvanen, 2013, Colistin methanesulfonate and colistin pharmacokinetics in critically ill patients receiving continuous venovenous hemodiafiltration, Antimicrob Agents Chemother, 57, 668, 10.1128/AAC.00985-12 Jelliffe, 2002, Estimation of creatinine clearance in patients with unstable renal function, without a urine specimen, Am J Nephrol, 22, 320, 10.1159/000065221 Nation, 2016, Updated US and European dose recommendations for intravenous colistin: how do they perform?, Clin Infect Dis, 62, 552, 10.1093/cid/civ964 Cheah, 2015, New pharmacokinetic/pharmacodynamic studies of systemically administered colistin against Pseudomonas aeruginosa and Acinetobacter baumannii in mouse thigh and lung infection models: smaller response in lung infection, J Antimicrob Chemother, 70, 3291 Ziaka, 2013, Combined intravenous and intraventricular administration of colistin methanesulfonate in critically ill patients with central nervous system infection, Antimicrob Agents Chemother, 57, 1938, 10.1128/AAC.01461-12 Yapa, 2014, Pulmonary and systemic pharmacokinetics of inhaled and intravenous colistin methanesulfonate in cystic fibrosis patients: targeting advantage of inhalational administration, Antimicrob Agents Chemother, 58, 2570, 10.1128/AAC.01705-13 Boisson, 2014, Comparison of intrapulmonary and systemic pharmacokinetics of colistin methanesulfonate (CMS) and colistin after aerosol delivery and intravenous administration of CMS in critically ill patients, Antimicrob Agents Chemother, 58, 7331, 10.1128/AAC.03510-14 Zavascki, 2007, Polymyxin B for the treatment of multidrug-resistant pathogens: a critical review, J Antimicrob Chemother, 60, 1206, 10.1093/jac/dkm357 Li, 2003, Use of high-performance liquid chromatography to study the pharmacokinetics of colistin sulfate in rats following intravenous administration, Antimicrob Agents Chemother, 47, 1766, 10.1128/AAC.47.5.1766-1770.2003 Sandri, 2013, Population pharmacokinetics of intravenous polymyxin B in critically ill patients: implications for selection of dosage regimens, Clin Infect Dis, 57, 524, 10.1093/cid/cit334 Banerjee, 2000, The treatment of respiratory Pseudomonas infection in cystic fibrosis: what drug and which way?, Drugs, 60, 1053, 10.2165/00003495-200060050-00006 Marschke, 1971, Polymyxin inhalation therapeutic hazard, Ann Intern Med, 74, 144, 10.7326/0003-4819-74-1-144 Owen, 2007, In vitro pharmacodynamics of colistin against Acinetobacter baumannii clinical isolates, J Antimicrob Chemother, 59, 473, 10.1093/jac/dkl512 Poudyal, 2008, In vitro pharmacodynamics of colistin against multidrug-resistant Klebsiella pneumoniae, J Antimicrob Chemother, 62, 1311, 10.1093/jac/dkn425 Bergen, 2010, Pharmacokinetic/pharmacodynamic investigation of colistin against Pseudomonas aeruginosa using an in vitro model, Antimicrob Agents Chemother, 54, 3783, 10.1128/AAC.00903-09 Tran, 2016, Anthelmintic closantel enhances bacterial killing of polymyxin B against multidrug-resistant Acinetobacter baumannii, J Antibiot (Tokyo), 69, 415, 10.1038/ja.2015.127 Abdul Rahim, 2015, Synergistic killing of NDM-producing MDR Klebsiella pneumoniae by two ‘old’ antibiotics—polymyxin B and chloramphenicol, J Antimicrob Chemother, 70, 2589, 10.1093/jac/dkv135 Tam, 2005, Pharmacodynamics of polymyxin B against Pseudomonas aeruginosa, Antimicrob Agents Chemother, 49, 3624, 10.1128/AAC.49.9.3624-3630.2005 Li, 2006, Heteroresistance to colistin in multidrug-resistant Acinetobacter baumannii, Antimicrob Agents Chemother, 50, 2946, 10.1128/AAC.00103-06 Meletis, 2011, Colistin heteroresistance in carbapenemase-producing Klebsiella pneumoniae, J Antimicrob Chemother, 66, 946, 10.1093/jac/dkr007 Bergen, 2011, Clinically relevant plasma concentrations of colistin in combination with imipenem enhance pharmacodynamic activity against multidrug-resistant Pseudomonas aeruginosa at multiple inocula, Antimicrob Agents Chemother, 55, 5134, 10.1128/AAC.05028-11 Fekety, 1962, The treatment of Gram-negative bacillary infections with colistin. The toxicity and efficacy of large doses in forty-eight patients, Ann Intern Med, 57, 214, 10.7326/0003-4819-57-2-214 Falagas, 2005, Toxicity after prolonged (more than four weeks) administration of intravenous colistin, BMC Infect Dis, 5, 1, 10.1186/1471-2334-5-1 Oliveira, 2009, Polymyxin B and colistimethate are comparable as to efficacy and renal toxicity, Diagn Microbiol Infect Dis, 65, 431, 10.1016/j.diagmicrobio.2009.07.018 Kubin, 2012, Incidence and predictors of acute kidney injury associated with intravenous polymyxin B therapy, J Infect, 65, 80, 10.1016/j.jinf.2012.01.015 Akajagbor, 2013, Higher incidence of acute kidney injury with intravenous colistimethate sodium compared with polymyxin B in critically ill patients at a tertiary care medical center, Clin Infect Dis, 57, 1300, 10.1093/cid/cit453 Phe, 2014, In vitro assessment and multicenter cohort study of comparative nephrotoxicity rates associated with colistimethate versus polymyxin B therapy, Antimicrob Agents Chemother, 58, 2740, 10.1128/AAC.02476-13 Sorlí, 2013, Trough colistin plasma level is an independent risk factor for nephrotoxicity: a prospective observational cohort study, BMC Infect Dis, 13, 380, 10.1186/1471-2334-13-380 Forrest, 2014 Rigatto, 2015, Risk factors for acute kidney injury (AKI) in patients treated with polymyxin B and influence of AKI on mortality: a multicentre prospective cohort study, J Antimicrob Chemother, 70, 1552, 10.1093/jac/dku561 Dubrovskaya, 2015, Risk factors for nephrotoxicity onset associated with polymyxin B therapy, J Antimicrob Chemother, 70, 1903, 10.1093/jac/dkv014 Suzuki, 2013, Megalin contributes to kidney accumulation and nephrotoxicity of colistin, Antimicrob Agents Chemother, 57, 6319, 10.1128/AAC.00254-13 Lu, 2016, Human oligopeptide transporter 2 (PEPT2) mediates cellular uptake of polymyxins, J Antimicrob Chemother, 71, 403, 10.1093/jac/dkv340 Azad, 2013, Polymyxin B induces apoptosis in kidney proximal tubular cells, Antimicrob Agents Chemother, 57, 4329, 10.1128/AAC.02587-12 Eadon, 2013, Cell cycle arrest in a model of colistin nephrotoxicity, Physiol Genomics, 45, 877, 10.1152/physiolgenomics.00076.2013